Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Potassium two pore domain channel subfamily K member 16 (KCNK16, TALK-1) is a voltage-dependent, outward rectifying potassium channel belonging to the two pore domain (K2P) family[1][2][7]. It is mainly activated in alkaline pH and expressed predominantly in the pancreas, particularly in pancreatic islets. The channel combines features of open rectification, preferentially passing outward K+ currents under physiological concentrations, which regulates the electrical excitability of β-cells and therefore insulin secretion[1][6]. KCNK16 orchestrates cytosolic and mitochondrial calcium oscillations, impacting second-phase insulin secretion and overall glucose homeostasis. Genetic variants have been linked to monogenic forms of diabetes (MODY) and other diabetes-related disorders[1][4][6]. The channel can form homo- and heterodimers, and may permeate other monovalent cations such as rubidium (Rb+) and cesium (Cs+)[1]. Its function is tightly linked to hormonal regulation, islet signaling, and metabolic stress adaptation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Potassium two pore domain channel subfamily K member 16 (KCNK16).